University of Ioannina
Επίδραση του συνδυασμού ορλιστάτης-φαινοφιμπράτης στις λιπιδαιμικές και μεταβολικές παραμέτρους σε υπέρβαρους και παχύσαρκους ασθενείς με μεταβολικό σύνδρομο
Abstract
dc:descriptionBackground: Obesity is a chronic condition, which constitutes an independent risk factor for themetabolic syndrome (MetS). The MetS increases the risk for cardiovascular disease (CVD).Objective: The present open-label randomized study evaluated the long-term effects of orlistat, fenofibrate and orlistat plus fenofibrate treatment on anthropometric variables, lipid profile, and carbohydrate metabolism, as well as on LDL and HDL phenotype and activities of atherosclerosis related enzymes, in overweight and obese patients [body mass index (BMI)>28 kg/m²] with MetS (defined by NCEP-ATPIII). Methods: Eighty-nine overweight and obese patients with MetS participated in the study. Patients were prescribed a low-calorie diet and randomized to receive for 6 months orlistat 120 mg TID (O group), micronized fenofibrate 200 mg/d (F group), or orlistat 120 mg TID plus micronized fenofibrate 200 mg/d (OF group). Results: Six patients dropped out, whereas eighty three patients completed the study, without any evidence of increased rate of adverse events in the combination group. After the first 3 months 43.5% of patients in the O group, 47.6% in the F group and 50% in the OF group no longer met the MetS diagnostic criteria (p<0.0001 vs. baseline in all treatment groups). Significant reductions in body weight, BMI, waist circumference, blood pressure, total cholesterol (TC), low-densitylipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), triglyceride (TG), insulin and homeostasis model assessment (HOMA) index levels were observed in all treatment groups. A greater improvement of anthropometric variables was observed in groups Oand OF compared with group F. In the group OF a greater decrease in TC and LDL-C was observed compared with that in the O and F groups (p<0.01) and a more pronounced reduction of TG levels compared with that in the O group (p<0.05). At the end of the 6-month treatment, a significant reduction of subjects with phenotype nonA, which is characterized by the presence of sdLDL, was observed. The reduction of the proportion of subjects with phenotype nonA was greater with the Fand OF administration compared with O administration (p<0.05). The reduction of small dense LDL-C (sdLDL-C), as well as the increase in both mean and peak LDL particle diameter were morepronounced with F and OF administration compared with O administration (p<0.05). Furthermore, the OF and F groups experienced greater reductions in the proportion of the sdLDL-C over the total LDL-C compared with the O administration (p<0.05). We observed a significant change in HDL-C levels only in F group. Large HDL-C levels were significantly increased and small HDL-C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL-C levels. No significant change of large or small HDL-C levels was observed with the combination treatment. We observed a significant increase of pre-beta1-HDL levels in all groups, which was significantly greater in OF group compared to O or F monotherapy. Lipoprotein associated phospholipase A₂ (LpPLA₂) was significantly reduced in all study groups. HDL-associated LpPLA₂ (HDL-LpPLA₂) was reduced in groups F and OF. Paraoxonase 1 (PON1) did not change in any group, whereas the PON1/LDL-C ratio was significantly increased in group OF compared with groups O and F. TG levels were reduced in all treatment groups. In O group we observed reductions of plasma apoC-III (p<0.05) and apoC-II (non-significant) levels. Fenofibrate administration significantly reduced the concentrations of apoC-II and apoC-III, whereas the combination of orlistat and fenofibrate had an additive effect on these apolipoproteins. Multivariate analysis showed that in O group baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In F group baseline TG levels and apoC-III reduction were significantly and independently correlated with TG reduction. In OF group baseline TG levels and apoC-III reduction were independently positively correlated and baseline apoC-II levels were negatively correlated with TG lowering. Plasma high sensitivity C-reactive protein was significantly reduced in all study groups, but no significant difference between them was observed. Visfatin plasma levels did not change in any study group. Conclusion: The orlistat and fenofibrate combination appears to be safe and may further improve the metabolic parameters of patients with the MetS compared with each monotherapy.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Filippatos, Theodosios
- Φιλιππάτος, Θεοδόσιος
Subjects
dc:subject × 20- Ορλιστάτη
- Φαινοφιμπράτη
- Μεταβολικό σύνδρομο
- Παχυσαρκία
- LDL υποκλάσματα
- HDL υποκλάσματα
- Λιποπρωτεϊνική φωσφολιπάση A₂
- Παραοξονάση
- Orlistat
- Fenofibrate
- Metabolic syndrome
- Obesity
- LDL subclasses
- HDL subclasses
- Lipoprotein associated phospholipase A2
- Paraoxonase
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26035